Definium Therapeutics, Inc. (DFTX) AI Stock Summary

Snapshot

Definium Therapeutics is a clinical-stage biotech burning cash to fund drug development, with no revenue yet. In FY 2025, the company reported a net loss of $183.8M against $0 in revenue, a standard profile for pre-revenue biotechs. The burn rate is high, but the balance sheet is strong: $411.6M in cash and zero debt provide a comfortable runway of roughly 19 months. The share count dropped 87% year-over-year, likely due to a reverse split, which concentrates ownership but does not change the underlying economics. The stock trades at $20.99, near the bottom of its 52-week range, reflecting investor caution ahead of pivotal trial results.

What's Happening Right Now

• Tue 12th May '26 · Clinical Trial: Definium dosed the first patient in Ascend, its second Phase 3 study for major depressive disorder.
• Fri 8th May '26 · Earnings: Q1 2026 results showed $373.4M in cash, with management expecting three key Phase 3 data readouts later this year.
• Sat 18th Apr '26 · Regulatory: The company supported a White House executive order aimed at accelerating research and access to psychedelic medical treatments.

Ownership

Institutions hold 8.6% of the company, while insiders hold 1.9%.

Bottom Line

Definium is a high-risk, high-reward bet on psychedelic-derived therapies for mental health. The company has no revenue and loses significant money each year, but it holds enough cash to fund operations into 2028 without raising new capital. The stock is trading near its lows, pricing in skepticism about whether its lead candidates will succeed in Phase 3 trials. Three major data readouts are expected in 2026, which will likely drive the next big move in the stock price. A reader should view this as a binary event-driven play rather than a traditional operating business.